TABLE 1.

Characteristics of patients with HAM/TSP enrolled in this study.

Hospital name	Patient no.	Age (years)	Sex	Disease duration	OMDS at baseline	mPSL dose (mg/day)	PSL dose from after pulse therapy until year 2 (mg/day)
Fukuoka University Hospital (FUH)	1	61	F	3 months	6	1000	0.0
	2	71	F	8 months	9	1000	50.0 → 10.0
	3	71	F	6 months	4	1000	0.0
	4	72	F	2 years	5	1000	0.0∗
	5	48	F	16 years	4	1000	0.0
	6	67	F	4 years	4	1000	20.0 → 5.0
	7	68	F	9 years	4	1000	0.0
St. Marianna University Hospital (SMUH)	8	58	F	1 year	6	1000	20.0 → 10.0
	9	53	M	2 years	6	250	40.0 → 7.0
	10	67	F	4 years	3	500	15.0 → 2.0
	11	33	F	17 years	6	500	20.0 → 5.0
	12	67	F	19 years	8	500	30.0 → 8.0
	13	62	F	10 years	6	1000	25.0 → 7.0
SMUH	14	71	F	18 years	5	0	N/A
	15	71	F	13 years	5	0	N/A
	16	59	F	1 year	1	0	N/A
	17	64	F	4 years	4	0	N/A
	18	45	F	10 years	4	0	N/A
Hospital name	Patient no.	Age (years)	Sex	Disease duration	OMDS at baseline	PSL dose (mg/day)
FUH	19	58	F	3 years	3	5
SMUH	20	59	F	12 years	5	3
	21	64	F	18 years	5	3
	22	67	F	4 years	4	5

OMDS, osame motor disability score; mPSL, methylprednisolone; PSL, prednisolone; F, female; M, male; N/A, not applicable. ^∗Patient no. 4 received oral prednisolone therapy from 3 months after treatment because of high levels of CXCL10 and neopterin (Figure 3).